Company news: Shire, Sanofi

Share this article:
Shire announced Wednesday that it is looking to expand the indication for its ADHD medication Vyvanse. The company is seeking approval for use of the stimulant as a maintenance drug for children between the ages of 6 and 17. It is currently cleared for maintenance therapy among adults. Approval would make it the only stimulant approved for maintenance among this age group. FDA's action date is April 29, 2013.

Sanofi is expected to clarify layoff plans at meetings September 25 and October 3, reported Reuters, which attributed the information to union sources. Reuters' sources said they expect Sanofi to cut about 2,500 research and support jobs in France. Sanofi told Reuters meeting dates had not been set, but that it will present its employment plans to the works council this month.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.